Gene-expression profiling has had a considerable impact on our understanding of breast
cancer biology. During the last 15 years, 5 intrinsic molecular subtypes of breast cancer …

Importance Estrogen receptor–positive (ER+) tumors of the breast are generally highly
responsive to endocrine treatment. Although endocrine therapy is the mainstay of adjuvant …

Background Preoperative and perioperative aromatase inhibitor (POAI) therapy has the
potential to improve outcomes in women with operable oestrogen receptor-positive primary …

PURPOSE The prognostic and predictive value of intrinsic subtypes in hormone receptor–
positive, human epidermal growth factor receptor 2–negative advanced breast cancer …

Uncontrolled proliferation is a hallmark of cancer. In breast cancer, immunohistochemical
assessment of the proportion of cells staining for the nuclear antigen Ki67 has become the …

Abstract Oestrogen receptor-positive (ER+) breast cancer is a major cause of cancer death
in women. Although aromatase inhibitors suppress the function of ER and reduce the risk of …

Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor
(ER)–positive primary breast cancer triaged to chemotherapy when the protein encoded by …

Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–
positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …

To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with
somatic alterations, we studied pretreatment tumour biopsies accrued from patients in two …

To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-
genome comparisons with originating breast cancers representative of the major intrinsic …